acute lymphoblastic leukemia, in relapse
Showing 1 - 25 of 26
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia With Failed Remission
-
São Paulo, SP, BrazilInstituto do Cancer do Estado de Sao Paulo
Sep 12, 2023
Determining the Mechanisms of Loss of CAR T Cell Persistence
Not yet recruiting
- Acute Lymphoblastic Leukemia With Failed Remission
- +4 more
- (no location specified)
Mar 29, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +4 more
- Ruxolitinib
- +5 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Feb 16, 2023
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +4 more
- Decitabine
- +3 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Feb 22, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- Cyclophosphamide
- +2 more
-
São Paulo, BrazilHospital Israelita Albert Einstein
Jan 20, 2023
MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)
Recruiting
- Myelodysplastic Syndromes, de Novo
- +10 more
- Venetoclax
- +10 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 23, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory Trial in Memphis (drug, device, biological)
Active, not recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia, Refractory
- Cyclophosphamide
- +4 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jan 3, 2023
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +4 more
- Trametinib
- +4 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Dec 13, 2022
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
- +4 more
-
Milwaukee, WisconsinMedical College of Wisconsin
Sep 22, 2022
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia Trial in Beijing
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- chimeric antigen receptor T cell
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Aug 12, 2022
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Beijing
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- Autologous humanized anti-CD22 chimeric antigen receptor T cells
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Aug 12, 2022
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL Trial in Memphis (biological,
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +2 more
- CD19-CAR(Mem) T-cells
- +5 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 5, 2022
B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse Trial (Decreasing starting times for beginning
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia, in Relapse
- Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )
- Nivolumab starting at day -1
- (no location specified)
Apr 4, 2022
Acute Lymphoblastic Leukemia, in Relapse Trial in Bergamo, Monza (CARCIK-CD19)
Active, not recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- CARCIK-CD19
-
Bergamo, BG, Italy
- +1 more
Feb 3, 2022
Acute Lymphoblastic Leukemia, in Relapse Trial in Belgium, France (GRASPA, L-asparaginase)
Completed
- Acute Lymphoblastic Leukemia, in Relapse
-
Bruxelles, Belgium
- +27 more
Feb 1, 2022
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric Trial in Denmark,
Recruiting
- Acute Lymphoblastic Leukemia
- +4 more
-
Copenhagen, Denmark
- +16 more
Jan 26, 2022
Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease Trial in Mexico City (Bortezomib)
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +2 more
-
Mexico City, MexicoHospital General de México "Dr. Eduardo Liceaga"
Jan 2, 2022
Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse Trial in Italy (Ponatinib)
Recruiting
- Philadelphia-Positive ALL
- Acute Lymphoblastic Leukemia, in Relapse
-
Ancona, Italy
- +21 more
Jan 3, 2022
Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, in Relapse Trial in Moscow (boost
Recruiting
- Acute Myeloid Leukemia
- +6 more
- boost anti-viral immunity after T-cell depleted HSCT
-
Moscow, Russian FederationFederal Research Center for pediatric hematology, oncology and i
Oct 1, 2021
Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Wuhan (pCAR-19B cells)
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- Refractory Acute Lymphoblastic Leukemia
- pCAR-19B cells
-
Wuhan, Hubei, ChinaTongji Hospital affiliated to Tongji Medical College of Huazhong
May 12, 2021
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic
Unknown status
- Acute Lymphoblastic Leukemia, in Relapse
- +2 more
- CD19-CAR-T2 Cells
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Oct 25, 2020
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse Trial in Hangzhou (CD19/BCMA
Recruiting
- Multiple Myeloma in Relapse
- +5 more
- CD19/BCMA Targeted CAR T-cells and dasatinib
- CD19/BCMA Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Oct 27, 2020
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in Memphis (Palbociclib Oral
Terminated
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia With Failed Remission
- Palbociclib Oral Capsule
- +6 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 28, 2020
Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapse Trial in
Unknown status
- Acute Lymphoblastic Leukemia Recurrent
- +4 more
- INA03 administration
-
Marseille, Bouches-du Rhône, France
- +1 more
Feb 4, 2020